A Patient Experience That Illustrates the Changing Treatment Landscape in Mantle Cell Lymphoma

Suchitra Sundaram, MD


January 19, 2023

Suchitra Sundaram, MD, reflects on a patient experience early in her career that exemplified the lack of therapeutic options for mantle cell lymphoma (MCL) available at that time. Since then, as Dr Sundaram notes, the advent of targeted and immunotherapies has made it possible for patients to achieve lasting disease control and remission without disturbing their daily lives.

Dr Sundaram also points to the recent approval of CAR T-cell immunotherapies available for patients with MCL as providing another option for patients who have progressed past one or two lines of therapy, though these treatments require an inpatient setting. Looking ahead, she also considers the possible revolutionary addition of bispecific antibodies, which can be delivered in an outpatient setting, as a potential option to treat patients in a way that fits their daily lives.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.